185 related articles for article (PubMed ID: 22860894)
1. Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and/or acute severe infusion reactions to infliximab in Crohn's disease.
Steenholdt C; Enevold C; Ainsworth MA; Brynskov J; Thomsen OØ; Bendtzen K
Aliment Pharmacol Ther; 2012 Oct; 36(7):650-9. PubMed ID: 22860894
[TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphisms of tumour necrosis factor receptor superfamily 1A and 1B affect responses to infliximab in Japanese patients with Crohn's disease.
Matsukura H; Ikeda S; Yoshimura N; Takazoe M; Muramatsu M
Aliment Pharmacol Ther; 2008 May; 27(9):765-70. PubMed ID: 18248655
[TBL] [Abstract][Full Text] [Related]
3. Role of TNFRSF1B polymorphisms in the response of Crohn's disease patients to infliximab.
Medrano LM; Taxonera C; Márquez A; Barreiro-de Acosta M; Gómez-García M; González-Artacho C; Pérez-Calle JL; Bermejo F; Lopez-Sanromán A; Martín Arranz MD; Gisbert JP; Mendoza JL; Martín J; Urcelay E; Núñez C
Hum Immunol; 2014 Jan; 75(1):71-5. PubMed ID: 24121042
[TBL] [Abstract][Full Text] [Related]
4. Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn's disease.
Netz U; Carter JV; Eichenberger MR; Dryden GW; Pan J; Rai SN; Galandiuk S
World J Gastroenterol; 2017 Jul; 23(27):4958-4967. PubMed ID: 28785150
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetic analysis of TNF, TNFRSF1A, and TNFRSF1B gene polymorphisms and prediction of response to anti-TNF therapy in psoriasis patients in the Greek population.
Vasilopoulos Y; Manolika M; Zafiriou E; Sarafidou T; Bagiatis V; Krüger-Krasagaki S; Tosca A; Patsatsi A; Sotiriadis D; Mamuris Z; Roussaki-Schulze A
Mol Diagn Ther; 2012 Feb; 16(1):29-34. PubMed ID: 22111980
[TBL] [Abstract][Full Text] [Related]
6. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab.
Pierik M; Vermeire S; Steen KV; Joossens S; Claessens G; Vlietinck R; Rutgeerts P
Aliment Pharmacol Ther; 2004 Aug; 20(3):303-10. PubMed ID: 15274667
[TBL] [Abstract][Full Text] [Related]
7. Role of TNFRSF1A and TNFRSF1B polymorphisms in susceptibility, severity, and therapeutic efficacy of etanercept in human leukocyte antigen-B27-positive Chinese Han patients with ankylosing spondylitis.
Xing-Rong W; Sheng-Qian X; Wen L; Shan Q; Fa-Ming P; Jian-Hua X
Medicine (Baltimore); 2018 Aug; 97(31):e11677. PubMed ID: 30075559
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.
Hlavaty T; Pierik M; Henckaerts L; Ferrante M; Joossens S; van Schuerbeek N; Noman M; Rutgeerts P; Vermeire S
Aliment Pharmacol Ther; 2005 Oct; 22(7):613-26. PubMed ID: 16181301
[TBL] [Abstract][Full Text] [Related]
9. Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn's disease.
Steenholdt C
Dan Med J; 2013 Apr; 60(4):B4616. PubMed ID: 23651723
[TBL] [Abstract][Full Text] [Related]
10. Genetic predictors of long-term response and trough levels of infliximab in crohn's disease.
Salvador-Martín S; López-Cauce B; Nuñez O; Laserna-Mendieta EJ; García MI; Lobato E; Abarca-Zabalía J; Sanjurjo-Saez M; Lucendo AJ; Marín-Jiménez I; Menchén LA; López-Fernández LA
Pharmacol Res; 2019 Nov; 149():104478. PubMed ID: 31605784
[TBL] [Abstract][Full Text] [Related]
11. The tumor necrosis factor receptor superfamily member 1B polymorphisms predict response to anti-TNF therapy in patients with autoimmune disease: A meta-analysis.
Chen W; Xu H; Wang X; Gu J; Xiong H; Shi Y
Int Immunopharmacol; 2015 Sep; 28(1):146-53. PubMed ID: 26071216
[TBL] [Abstract][Full Text] [Related]
12. Tumor necrosis factor receptor gene polymorphisms in Crohn's disease: association with clinical phenotypes.
Waschke KA; Villani AC; Vermeire S; Dufresne L; Chen TC; Bitton A; Cohen A; Thomson AB; Wild GE
Am J Gastroenterol; 2005 May; 100(5):1126-33. PubMed ID: 15842589
[TBL] [Abstract][Full Text] [Related]
13. Association of TNF-α, TNFRSF1A and TNFRSF1B gene polymorphisms with the risk of sporadic breast cancer in northeast Chinese Han women.
Xu F; Zhou G; Han S; Yuan W; Chen S; Fu Z; Li D; Zhang H; Li D; Pang D
PLoS One; 2014; 9(7):e101138. PubMed ID: 25010932
[TBL] [Abstract][Full Text] [Related]
14. Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial.
Buhl SS; Steenholdt C; Brynskov J; Thomsen OØ; Bendtzen K; Ainsworth MA
BMJ Open; 2014 Dec; 4(12):e005887. PubMed ID: 25524543
[TBL] [Abstract][Full Text] [Related]
15. Factors predicting the therapeutic response to infliximab during maintenance therapy in Japanese patients with Crohn's disease.
Matsuoka K; Hamada S; Shimizu M; Nanki K; Mizuno S; Kiyohara H; Arai M; Sugimoto S; Iwao Y; Ogata H; Hisamatsu T; Naganuma M; Kanai T; Mochizuki M; Hashiguchi M
PLoS One; 2018; 13(10):e0204632. PubMed ID: 30286108
[TBL] [Abstract][Full Text] [Related]
16. Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF.
Yamada A; Sono K; Hosoe N; Takada N; Suzuki Y
Inflamm Bowel Dis; 2010 Nov; 16(11):1898-904. PubMed ID: 20310016
[TBL] [Abstract][Full Text] [Related]
17. Elective switching from infliximab to adalimumab in stable Crohn's disease.
Hoentjen F; Haarhuis BJ; Drenth JP; de Jong DJ
Inflamm Bowel Dis; 2013; 19(4):761-6. PubMed ID: 23446337
[TBL] [Abstract][Full Text] [Related]
18. Polymorphisms of the TNF gene and the TNF receptor superfamily member 1B gene are associated with susceptibility to ulcerative colitis and Crohn's disease, respectively.
Sashio H; Tamura K; Ito R; Yamamoto Y; Bamba H; Kosaka T; Fukui S; Sawada K; Fukuda Y; Tamura K; Satomi M; Shimoyama T; Furuyama J
Immunogenetics; 2002 Mar; 53(12):1020-7. PubMed ID: 11904678
[TBL] [Abstract][Full Text] [Related]
19. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
Baert F; Noman M; Vermeire S; Van Assche G; D' Haens G; Carbonez A; Rutgeerts P
N Engl J Med; 2003 Feb; 348(7):601-8. PubMed ID: 12584368
[TBL] [Abstract][Full Text] [Related]
20. Single nucleotide polymorphisms in ADAM17, IL23R and SLCO1C1 genes protect against infliximab failure in adults with Crohn's disease.
Laserna-Mendieta EJ; Salvador-Martín S; Arias A; López-Cauce B; Marín-Jiménez I; Menchén LA; Marín-Rubio L; Ontañón Rodríguez J; López-Fernández LA; Lucendo AJ
Biomed Pharmacother; 2023 Mar; 159():114225. PubMed ID: 36621146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
